Liberate Bio utilizes the proprietary RAPTOR™ platform to discover scalable _in vivo_ delivery solutions for genetic payloads. This system enables targeted delivery to historically inaccessible cell populations, including myeloid lineages and bone marrow. The company applies this technology to develop novel therapeutics for hematologic cancers and autoimmune diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current genetic medicines face delivery challenges, often limited to the liver due to inefficient and non-targeted delivery methods. This restricts the therapeutic potential of nucleic acid cargoes like ASOs, siRNAs, mRNAs, and gene editors for treating diseases in other tissues. Existing trial-and-error processes for developing delivery vehicles are slow and costly, hindering the progress of genetic medicine.
Solution
Liberate Bio is developing non-viral delivery technologies for genetic medicines, utilizing in vivo high-throughput screening and machine learning to create targeted delivery vehicles for nucleic acid cargoes. The company's RAPTOR™ platform employs AI to accelerate the discovery of novel extrahepatic delivery vehicles by directly testing hundreds of lipid nanoparticles (LNPs) in non-human primates (NHPs). This approach generates human-relevant data at a fraction of the cost compared to traditional methods, enabling precise delivery to disease-relevant tissues and unlocking the full potential of genetic medicines. Liberate Bio's platform expands beyond lipid technologies to enhance delivery to a wider range of tissues.
Target Audience
Liberate Bio's primary target audience includes pharmaceutical companies and research institutions focused on developing genetic medicines and nucleic acid therapeutics, particularly those seeking to expand beyond liver-targeted delivery.
Features
- RAPTOR™ platform: AI-driven system for scalable extrahepatic genetic medicine delivery.
- In vivo high-throughput screening of barcoded cargoes in non-human primates.
- Machine learning algorithms to identify novel lipids and LNP formulations.
- Development of non-lipid delivery technologies.
- Enhanced delivery to disease-relevant tissues beyond the liver.